-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsToday Rivus announced that its dinitrophenol (DNP) prodrug, HU6, achieved a primary endpoint in a Phase II trial in fatty liver disease
.
This trial enrolled 80 obese patients with fatty liver and compared the effect of three doses of HU6 and placebo on liver fat content
Drug source analysis
Drug source analysisRivus received $35 million in Series A backing from Longitude, Medicxi, and Rx Capital last year, and HU6 appears to have been acquired from Sanyal
.
Rivus' technology platform is called controlled metabolic accelerators (CMAs), and HU6 is a core asset that has entered early clinical trials for type 2 diabetes, NASH, severe hypertriglyceridemia, and heart failure (HFpEF)
The chemical structure of HU6 has not been published, so it is not known how the release of the original drug is controlled by feedback
.
DNP is a mitochondrial decoupling agent, which can convert the energy generated by mitochondrial oxidation into heat energy and accelerate energy consumption
DNP has a super fat-burning ability and has been verified on a large scale in the human body, but its safety is very poor
.
So DNP is similar to the highly toxic warhead in the ADC design, but it's just a metabolic warhead